{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:12:48Z","timestamp":1792642368188,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The use of therapeutic drug monitoring (TDM) for antiseizure medications (ASMs) may contribute to treatment optimization in individual patients. This study included patients with Dravet syndrome as they often require close monitoring because of polypharmacy with various ASMs. The aim was to use long-term TDM to investigate pharmacokinetic variability of ASMs in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective data from patients with Dravet syndrome were collected from the TDM database at the Section for Clinical Pharmacology, National Center for Epilepsy in Norway (2008\u20132018). Concentration\/(dose\/kg)ratios (C\/D ratios) were calculated for the ASMs and the concentration (C\/C ratio) for N-desmethylclobazam. In patients with at least 3 measurements, the CV for C\/D ratios for intrapatient and interpatient variability was calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifty-three patients (30 male patients\/23 female patients) between 2 and 50 years of age (mean, 16 years) were included. Pharmacokinetic variability of the total number of measurements of valproate (n = 417), clobazam and N-desmethylclobazam (n = 328), and levetiracetam (n = 238) was determined. Interpatient variability was more pronounced than intrapatient variability (coefficient of variations: valproate, 65% vs. 24%; levetiracetam, 71% vs. 27%; and clobazam\/N-desmethylclobazam, 47%\/77% vs. 35%\/55%) (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). Comedication with stiripentol (n = 16) increased the C\/D ratio of valproate by 63% and of clobazam by 133% and the C\/C ratio of N-desmethylclobazam\/clobazam by 104% (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). Younger age also contributed to pharmacokinetic variability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Long-term TDM revealed extensive variability in serum concentrations over time; the variability was lowest for levetiracetam, moderate for valproate, and highest for clobazam. Pharmacokinetic variability and interactions can thus be identified and adjusted to facilitate decision making to achieve the optimal treatment outcome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000781","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T05:01:40Z","timestamp":1595480500000},"page":"744-753","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome"],"prefix":"10.1097","volume":"42","author":[{"given":"Cecilie","family":"Johannessen Landmark","sequence":"first","affiliation":[{"name":"Program for Pharmacy, Department of Life Sciences and Health, Faculty of Health Sciences, Oslo Metropolitan University;"},{"name":"The National Center for Epilepsy, Sandvika, Oslo University Hospital;"},{"name":"Section for Clinical Pharmacology, The National Center for Epilepsy, Department of Pharmacology, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Heger","sequence":"additional","affiliation":[{"name":"Program for Pharmacy, Department of Life Sciences and Health, Faculty of Health Sciences, Oslo Metropolitan University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Rare Genetic Syndromes, Oslo University Hospital; and"},{"name":"Department of Neurohabilitation, Oslo University Hospital, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margrete Larsen","family":"Burns","sequence":"additional","affiliation":[{"name":"Section for Clinical Pharmacology, The National Center for Epilepsy, Department of Pharmacology, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Bj\u00f8rnvold","sequence":"additional","affiliation":[{"name":"The National Center for Epilepsy, Sandvika, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"S\u00e6tre","sequence":"additional","affiliation":[{"name":"The National Center for Epilepsy, Sandvika, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein I.","family":"Johannessen","sequence":"additional","affiliation":[{"name":"The National Center for Epilepsy, Sandvika, Oslo University Hospital;"},{"name":"Section for Clinical Pharmacology, The National Center for Epilepsy, Department of Pharmacology, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-20230928","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia."},{"issue":"suppl 3","key":"R2-20230928","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1017\/cjn.2016.249","article-title":"Treatment of Dravet syndrome","volume":"43","author":"Wirrell","year":"2016","journal-title":"Can J Neurol Sci."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pediatr Neurol."},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40263-018-0511-y","article-title":"Treatment strategies for Dravet syndrome","volume":"32","author":"Knupp","year":"2018","journal-title":"CNS Drugs."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dmcn.13591","article-title":"Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey","volume":"60","author":"Lagae","year":"2018","journal-title":"Dev Med Child Neurol."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.addr.2011.10.003","article-title":"Host factors affecting antiepileptic drug delivery-pharmacokinetic variability","volume":"64","author":"Johannessen Landmark","year":"2012","journal-title":"Adv Drug Deliv Rev."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","article-title":"Dosing strategies for antiepileptic drugs: from a standard dose for all to individualized treatment by implementation of therapeutic drug monitoring","volume":"18","author":"Landmark","year":"2016","journal-title":"Epileptic Disord."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drug: current status and future prospects","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Exp Opin Drug Metab Toxicol."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/epi.12303","article-title":"Stiripentol in Dravet syndrome: results of a retrospective U.S. study","volume":"54","author":"Wirrell","year":"2013","journal-title":"Epilepsia."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1528-1167.2009.02466.x","article-title":"A long-term follow-up study of Dravet syndrome up to adulthood","volume":"51","author":"Akiyama","year":"2010","journal-title":"Epilepsia."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"106148","DOI":"10.1016\/j.eplepsyres.2019.05.016","article-title":"Long term therapeutic drug monitoring of antiepileptic drugs in patients with JME","volume":"155","author":"Johannessen Landmark","year":"2019","journal-title":"Epilepsy Res."},{"key":"R15-20230928","first-page":"271","article-title":"Reference ranges of antiepileptic drugs revisited-a practical approach to establish national guidelines","volume":"12","author":"Reimers","year":"2018","journal-title":"Clin Pharm Ther."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","article-title":"Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes","volume":"32","author":"Walzer","year":"2012","journal-title":"Pharmacotherapy."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0000000000000272","article-title":"Therapeutic drug monitoring of clobazam and its metabolite\u2014impact of age and comedication on pharmacokinetic variability","volume":"38","author":"Burns","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","article-title":"Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies","volume":"35","author":"De Leon","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/phar.2012","article-title":"Factors in variability of serial gabapentin concentrations in elderly patients with epilepsy","volume":"37","author":"Conway","year":"2017","journal-title":"Pharmacother."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FTD.0b013e31825dc4a6","article-title":"Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication","volume":"34","author":"May","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/epi.13802","article-title":"Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations","volume":"58","author":"Patsalos","year":"2017","journal-title":"Epilepsia."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-013-0067-4","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update","volume":"8","author":"Italiano","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17425255.2019.1575361","article-title":"Pharmacokinetic considerations for anti-epileptic drugs in children","volume":"15","author":"Verotti","year":"2019","journal-title":"Exp Opin Drug Metab Toxicol."},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00002826-198512000-00007","article-title":"Free level monitoring of carbamazepine and valproic acid: clinical significance","volume":"8","author":"Fr\u00f6scher","year":"1985","journal-title":"Clin Neuropharmacol."},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2018.02.004","article-title":"Pharmacokinetic variability of valproate during pregnancy\u2013implications for the use of therapeutic drug monitoring","volume":"141","author":"Landmark","year":"2018","journal-title":"Epilepsy Res."},{"issue":"suppl 1","key":"R27-20230928","first-page":"S16","article-title":"Pharmacology and drug interactions of cannabinoids","volume":"22","author":"Landmark","year":"2020","journal-title":"Epileptic Disord."},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev."},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second and third generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Exp Rev Neurother."},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s11064-017-2234-8","article-title":"Therapeutic drug monitoring of lacosamide in Norway: pharmacokinetic variability, clinical efficacy and tolerability","volume":"42","author":"Svendsen","year":"2017","journal-title":"Neurochem Res."},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ane.12578","article-title":"Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs","volume":"135","author":"Mevaag","year":"2017","journal-title":"Acta Neurol Scand."},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/epi4.12367","article-title":"Refractory epilepsy and nonadherence to drug treatment","volume":"4","author":"Henning","year":"2019","journal-title":"Epilepsia Open."},{"key":"R33-20230928","doi-asserted-by":"crossref","DOI":"10.1002\/epi4.12413","article-title":"A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway","author":"Heger","year":"2020","journal-title":"Epilepsia Open"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:05:43Z","timestamp":1695863143000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000781","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}